T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy

C. J. Kirk, Dennis Hartigan-O'Connor, B. J. Nickoloff, J. S. Chamberlain, M. Giedlin, L. Aukerman, J. J. Mulé

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

Secondary lymphoid tissue chemokine (SLC) is a CC chemokine that is selective in its recruitment of naïve T cells and dendritic cells (DCs). In the lymph node, SLC is believed to play an important role in the initiation of an immune response by colocalizing naïve T cells with DC-presenting antigen. Here, we used SLC as a treatment for tumors established from the poorly immunogenic B16 melanoma. Intratumoral injections of SLC inhibited tumor growth in a CD8+, T cell-dependent manner. SLC elicited a substantial infiltration of DCs and T cells into the tumor, coincident with the antitumor response. We next used SLC gene-modified DCs as a treatment of established tumors. Intratumoral injections of SLC-expressing DCs resulted in tumor growth inhibition that was significantly better than either control DCs or SLC alone. Distal site immunization of tumor-bearing mice with SLC gene-modified DCs pulsed with tumor lysate elicited an antitumor response whereas control DCs did not. We also found that s.c. injection of lysate-pulsed DCs expressing SLC promoted the migration of T cells to the immunization site. This report demonstrates that SLC can both induce antitumor responses and enhance the antitumor immunity elicited by DCs.

Original languageEnglish (US)
Pages (from-to)2062-2070
Number of pages9
JournalCancer Research
Volume61
Issue number5
StatePublished - Mar 1 2001
Externally publishedYes

Fingerprint

Chemokine CCL21
Immunotherapy
Dendritic Cells
Immunity
T-Lymphocytes
Neoplasms
Injections
Immunization
CC Chemokines
Experimental Melanomas
Growth
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kirk, C. J., Hartigan-O'Connor, D., Nickoloff, B. J., Chamberlain, J. S., Giedlin, M., Aukerman, L., & Mulé, J. J. (2001). T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy. Cancer Research, 61(5), 2062-2070.

T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine : Augmentation of dendritic cell-based immunotherapy. / Kirk, C. J.; Hartigan-O'Connor, Dennis; Nickoloff, B. J.; Chamberlain, J. S.; Giedlin, M.; Aukerman, L.; Mulé, J. J.

In: Cancer Research, Vol. 61, No. 5, 01.03.2001, p. 2062-2070.

Research output: Contribution to journalArticle

Kirk, CJ, Hartigan-O'Connor, D, Nickoloff, BJ, Chamberlain, JS, Giedlin, M, Aukerman, L & Mulé, JJ 2001, 'T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy', Cancer Research, vol. 61, no. 5, pp. 2062-2070.
Kirk, C. J. ; Hartigan-O'Connor, Dennis ; Nickoloff, B. J. ; Chamberlain, J. S. ; Giedlin, M. ; Aukerman, L. ; Mulé, J. J. / T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine : Augmentation of dendritic cell-based immunotherapy. In: Cancer Research. 2001 ; Vol. 61, No. 5. pp. 2062-2070.
@article{c75baad9f7514fda838034877bc278aa,
title = "T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy",
abstract = "Secondary lymphoid tissue chemokine (SLC) is a CC chemokine that is selective in its recruitment of na{\"i}ve T cells and dendritic cells (DCs). In the lymph node, SLC is believed to play an important role in the initiation of an immune response by colocalizing na{\"i}ve T cells with DC-presenting antigen. Here, we used SLC as a treatment for tumors established from the poorly immunogenic B16 melanoma. Intratumoral injections of SLC inhibited tumor growth in a CD8+, T cell-dependent manner. SLC elicited a substantial infiltration of DCs and T cells into the tumor, coincident with the antitumor response. We next used SLC gene-modified DCs as a treatment of established tumors. Intratumoral injections of SLC-expressing DCs resulted in tumor growth inhibition that was significantly better than either control DCs or SLC alone. Distal site immunization of tumor-bearing mice with SLC gene-modified DCs pulsed with tumor lysate elicited an antitumor response whereas control DCs did not. We also found that s.c. injection of lysate-pulsed DCs expressing SLC promoted the migration of T cells to the immunization site. This report demonstrates that SLC can both induce antitumor responses and enhance the antitumor immunity elicited by DCs.",
author = "Kirk, {C. J.} and Dennis Hartigan-O'Connor and Nickoloff, {B. J.} and Chamberlain, {J. S.} and M. Giedlin and L. Aukerman and Mul{\'e}, {J. J.}",
year = "2001",
month = "3",
day = "1",
language = "English (US)",
volume = "61",
pages = "2062--2070",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine

T2 - Augmentation of dendritic cell-based immunotherapy

AU - Kirk, C. J.

AU - Hartigan-O'Connor, Dennis

AU - Nickoloff, B. J.

AU - Chamberlain, J. S.

AU - Giedlin, M.

AU - Aukerman, L.

AU - Mulé, J. J.

PY - 2001/3/1

Y1 - 2001/3/1

N2 - Secondary lymphoid tissue chemokine (SLC) is a CC chemokine that is selective in its recruitment of naïve T cells and dendritic cells (DCs). In the lymph node, SLC is believed to play an important role in the initiation of an immune response by colocalizing naïve T cells with DC-presenting antigen. Here, we used SLC as a treatment for tumors established from the poorly immunogenic B16 melanoma. Intratumoral injections of SLC inhibited tumor growth in a CD8+, T cell-dependent manner. SLC elicited a substantial infiltration of DCs and T cells into the tumor, coincident with the antitumor response. We next used SLC gene-modified DCs as a treatment of established tumors. Intratumoral injections of SLC-expressing DCs resulted in tumor growth inhibition that was significantly better than either control DCs or SLC alone. Distal site immunization of tumor-bearing mice with SLC gene-modified DCs pulsed with tumor lysate elicited an antitumor response whereas control DCs did not. We also found that s.c. injection of lysate-pulsed DCs expressing SLC promoted the migration of T cells to the immunization site. This report demonstrates that SLC can both induce antitumor responses and enhance the antitumor immunity elicited by DCs.

AB - Secondary lymphoid tissue chemokine (SLC) is a CC chemokine that is selective in its recruitment of naïve T cells and dendritic cells (DCs). In the lymph node, SLC is believed to play an important role in the initiation of an immune response by colocalizing naïve T cells with DC-presenting antigen. Here, we used SLC as a treatment for tumors established from the poorly immunogenic B16 melanoma. Intratumoral injections of SLC inhibited tumor growth in a CD8+, T cell-dependent manner. SLC elicited a substantial infiltration of DCs and T cells into the tumor, coincident with the antitumor response. We next used SLC gene-modified DCs as a treatment of established tumors. Intratumoral injections of SLC-expressing DCs resulted in tumor growth inhibition that was significantly better than either control DCs or SLC alone. Distal site immunization of tumor-bearing mice with SLC gene-modified DCs pulsed with tumor lysate elicited an antitumor response whereas control DCs did not. We also found that s.c. injection of lysate-pulsed DCs expressing SLC promoted the migration of T cells to the immunization site. This report demonstrates that SLC can both induce antitumor responses and enhance the antitumor immunity elicited by DCs.

UR - http://www.scopus.com/inward/record.url?scp=0035266293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035266293&partnerID=8YFLogxK

M3 - Article

C2 - 11280767

AN - SCOPUS:0035266293

VL - 61

SP - 2062

EP - 2070

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 5

ER -